Autologous designer antigen-presenting cells by gene modification of T lymphocyte blasts with IL-7 and IL-12

Journal of Immunotherapy

Volumn 30, Issue 5, 2007, Pages 506-516

  Foster, Aaron E ^a   Leen, Ann M ^a   Lee, Timothy ^a,b   Okamura, Takayuki ^a   Lu, An ^a   Vera, Juan ^a   Atkinson, Rachel ^a   Bollard, Catherine M ^a   Dotti, Gianpietro ^a   Rooney, Cliona M ^a,c  

^a TEXAS CHILDREN S HOSPITAL   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c CENTER FOR CELL AND GENE THERAPY   (United States)

Author keywords

Antigen presenting cell; Immunotherapy; T lymphocyte

Indexed keywords

CD28 ANTIGEN; CD3 ANTIGEN; CD8 ANTIGEN; HLA A2 ANTIGEN; INTERLEUKIN 12; INTERLEUKIN 7; MELAN A; MELANOMA ANTIGEN 3;

ANTIGEN EXPRESSION; ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; DNA MODIFICATION; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IMMUNOSTIMULATION; MEMORY CELL; PRIORITY JOURNAL; T LYMPHOBLAST; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY;

ANTIGEN-PRESENTING CELLS; ANTIGENS, CD80; ANTIGENS, CD86; ANTIGENS, NEOPLASM; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; HUMANS; INTERLEUKIN-12; INTERLEUKIN-7; LYMPH NODES; LYMPHOCYTE ACTIVATION; NEOPLASM PROTEINS; PHOSPHOPROTEINS; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES; T-LYMPHOCYTES, CYTOTOXIC; VIRAL MATRIX PROTEINS;

EID: 34250896852     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e318046f3b1     Document Type: Article

References (48)

1. Cooper LJ, Al Kadhimi Z, Serrano LM, et al. Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1. Blood. 2005;105:1622-1631.
2. Naota H, Miyahara Y, Okumura S, et al. Generation of peptide-specific CD8+ T cells by phytohemagglutinin-stimulated antigen-mRNA-transduced CD4+ T cells. J Immunol Methods. 2006;314:54-66.
3. Salgado FJ, Lojo J, Fernandez-Alonso CM, et al. Interleukin-dependent modulation of HLA-DR expression on CD4 and CD8 activated T cells. Immunol Cell Biol. 2002;80:138-147.
4. Atanackovic D, Matsuo M, Ritter E, et al. Monitoring CD4+ T cell responses against viral and tumor antigens using T cells as novel target APC. J Immunol Methods. 2003;278:57-66.
5. Melenhorst JJ, Solomon SR, Shenoy A, et al. Robust expansion of viral antigen-specific CD4+ and CD8+ T cells for adoptive T cell therapy using gene-modified activated T cells as antigen presenting cells. J Immunother. 2006;29:436-443.
6. Berger C, Flowers ME, Warren EH, et al. Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK-modified donor T cells after allogeneic hematopoietic cell transplantation. Blood. 2006;107:2294-2302.
7. Riddell SR, Elliott M, Lewinsohn DA, et al. T-cell mediated rejection of gene-modified HIV-specific cytotoxic T lymphocytes in HIV-infected patients. Nat Med. 1996;2:216-223.
8. LaSalle JM, Ota K, Hafler DA. Presentation of autoantigen by human T cells. J Immunol. 1991;147:774-780.
9. LaSalle JM, Tolentino PJ, Freeman GJ, et al. Early signaling defects in human T cells anergized by T cell presentation of autoantigen. J Exp Med. 1992;176:177-186.
10. Mannie MD, Rendall SK, Arnold PY, et al. Anergy-associated T cell antigen presentation. A mechanism of infectious tolerance in experimental autoimmune encephalomyelitis. J Immunol. 1996;157:1062-1070.
11. Young KJ, Zhang L. The nature and mechanisms of DN regulatory T-cell mediated suppression. Hum Immunol. 2002;63:926-934.
12. Zhang ZX, Yang L, Young KJ, et al. Identification of a previously unknown antigen-specific regulatory T cell and its mechanism of suppression. Nat Med. 2000;6:782-789.
13. Huang JF, Yang Y, Sepulveda H, et al. TCR-mediated internalization of peptide-MHC complexes acquired by T cells. Science. 1999;286:952-954.
14. Huster KM, Busch V, Schiemann M, et al. Selective expression of IL-7 receptor on memory T cells identifies early CD40L-dependent generation of distinct CD8+ memory T cell subsets. Proc Natl Acad Sci U S A. 2004;101:5610-5615.
15. Madakamutil LT, Christen U, Lena CJ, et al. CD8alphaalpha-mediated survival and differentiation of CD8 memory T cell precursors. Science. 2004;304:590-593.
16. Wang LX, Li R, Yang G, et al. Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing. Cancer Res. 2005;65:10569-10577.
17. Wherry EJ, Teichgraber V, Becker TC, et al. Lineage relationship and protective immunity of memory CD8T cell subsets. Nat Immunol. 2003;4:225-234.
18. Mehrotra PT, Grant AJ, Siegel JP. Synergistic effects of IL-7 and IL-12 on human T cell activation. J Immunol. 1995;154:5093-5102.
19. Fujie T, Tanaka F, Mori M, et al. Induction of antitumor cytotoxic T lymphocytes from the peripheral blood mononuclear cells of cancer patients using HLA-A2-restricted MAGE-3 peptide in vitro. Clin Cancer Res. 1997;3:2425-2430.
20. van der BP, Bastin J, Gajewski T, et al. A peptide encoded by human gene MAGE-3 and presented by HLA-A2 induces cytolytic T lymphocytes that recognize tumor cells expressing MAGE-3. Eur J Immunol. 1994;24:3038-3043.
21. Valmori D, Fonteneau JF, Lizana CM, et al. Enhanced generation of specific tumor-reactive CTL in vitro by selected Melan-A/MART-1 immunodominant peptide analogues. J Immunol. 1998;160:1750-1758.
22. Wagner HJ, Bollard CM, Vigouroux S, et al. A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cells. Cancer Gene Ther. 2004;11:81-91.
23. Anderson R, Macdonald I, Corbett T, et al. Construction and biological characterization of an interleukin-12 fusion protein (Flexi-12): delivery to acute myeloid leukemic blasts using adeno-associated virus. Hum Gene Ther. 1997;8:1125-1135.
24. Gottschalk S, Edwards OL, Sili U, et al. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood. 2003;101:1905-1912.
25. Leen AM, Sili U, Vanin EF, et al. Conserved CTL epitopes on the adenovirus hexon protein expand subgroup cross-reactive and subgroup-specific CD8+ T cells. Blood. 2004;104:2432-2440.
26. Comoli P, Ginevri F, Maccario R, et al. Successful in vitro priming of EBV-specific CD8+ T cells endowed with strong cytotoxic function from T cells of EBV-seronegative children. Am J Transplant. 2006;6:2169-2176.
27. Kim JV, Latouche JB, Riviere I, et al. The ABCs of artificial antigen presentation. Nat Biotechnol. 2004;22:403-410.
28. Latouche JB, Sadelain M. Induction of human cytotoxic T lymphocytes by artificial antigen-presenting cells. Nat Biotechnol. 2000;18:405-409.
29. Daniel PT, Kroidl A, Cayeux S, et al. Costimulatory signals through B7.1/CD28 prevent T cell apoptosis during target cell lysis. J Immunol. 1997;159:3808-3815.
30. Lenschow DJ, Walunas TL, Bluestone JA. CD28/B7 system of T cell costimulation. Annu Rev Immunol. 1996;14:233-258.
31. Dhodapkar MV, Steinman RM. Antigen-bearing immature dendritic cells induce peptide-specific CD8(+) regulatory T cells in vivo in humans. Blood. 2002;100:174-177.
32. Dhodapkar MV, Steinman RM, Krasovsky J, et al. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med. 2001;193:233-238.
33. Jonuleit H, Schmitt E, Schuler G, et al. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med. 2000;192:1213-1222.
34. Satyaraj E, Rath S, Bal V. Induction of tolerance in freshly isolated alloreactive T cells by activated T cell stimulators is not due to the absence of CD28-B7 interaction. J Immunol. 1995;155:4669-4675.
35. Collette Y, Benziane A, Razanajaona D, et al. Distinct regulation of T-cell death by CD28 depending on both its aggregation and T-cell receptor triggering: a role for Fas-FasL. Blood. 1998;92:1350-1363.
36. Hirano N, Butler MO, Xia Z, et al. Engagement of CD83 ligand induces prolonged expansion of CD8+ T cells and preferential enrichment for antigen specificity. Blood. 2006;107:1528-1536.
37. Kos FJ, Mullbacher A. IL-2-independent activity of IL-7 in the generation of secondary antigen-specific cytotoxic T cell responses in vitro. J Immunol. 1993;150:387-393.
38. Lynch DH, Miller RE. Interleukin 7 promotes long-term in vitro growth of antitumor cytotoxic T lymphocytes with immunotherapeutic efficacy in vivo. J Exp Med. 1994;179:31-42.
39. Vonderheide RH, Hahn WC, Schultze JL, et al. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cytotoxic T lymphocytes. Immunity. 1999;10:673-679.
40. Yee C, Savage PA, Lee PP, et al. Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J Immunol. 1999;162:2227-2234.
41. Brunda MJ. Interleukin-12. J Leukoc Biol. 1994;55:280-288.
42. Robertson MJ, Soiffer RJ, Wolf SF, et al. Response of human natural killer (NK) cells to NK cell stimulatory factor (NKSF): cytolytic activity and proliferation of NK cells are differentially regulated by NKSF. J Exp Med. 1992;175:779-788.
43. Hsieh CS, Macatonia SE, Tripp CS, et al. Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science. 1993;260:547-549.
44. Seder RA, Gazzinelli R, Sher A, et al. Interleukin 12 acts directly on CD4+ T cells to enhance priming for interferon gamma production and diminishes interleukin 4 inhibition of such priming. Proc Natl Acad Sci U S A. 1993;90:10188-10192.
45. Montagna D, Maccario R, Locatelli F, et al. Ex vivo priming for long-term maintenance of antileukemia human cytotoxic T cells suggests a general procedure for adoptive immunotherapy. Blood. 2001;98:3359-3366.
46. Leonard JP, Sherman ML, Fisher GL, et al. Effects of single-dose interleukin-12 exposure on interleukin-12-associated toxicity and interferon-gamma production. Blood. 1997;90:2541-2548.
47. Yee C, Thompson JA, Byrd D, et al. Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A. 2002;99:16168-16173.
48. Bollard CM, Aguilar L, Straathof KC, et al. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med. 2004;200:1623-1633.